glp-1 and sibo Diagnostic Evaluation of an Increased Risk of Developing Small Intestinal Bacterial Overgrowth Associated with Glucagon-like Peptide-1 (GLP-1) Receptor Agonists Dual GLP-1/GIP Receptor Agonists: A Global Retrospective Multicenter Cohort Analysis sibo and glp 1 New
Description
Research to better understand and ultimately mitigate this heightened susceptibility is an important priority for new drug development in this area, and novel approaches to model the impact of endogenous hormone signaling will be critical to developing better treatments for more people
Target Evolution Single-target GLP-1 agonists are becoming a red ocean
Depommier, C., Everard, A., Druart, C., Plovier, H., Van Hul, M., Vieira-Silva, S., Falony, G., Raes, J., Maiter, D., Delzenne, N
A spoon is lifting some of the soup from the bowl
Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, including with its GLP-1 medications.
Codeage GLP-1 Probiotic+ is carefully formulated to meet the needs of individuals with dietary restrictions
